A Study of LY3214996 in Healthy Participants

Disposition of [14C]-LY3214996 Following Oral Administration in Healthy Male Subjects

The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study will involve a single dose of 14C radiolabelled LY3214996. This means that a radioactive substance, C14, will be incorporated into the study drug. The purposes are to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine and feces. The study will last up to six weeks.

Inclusion Criteria:

• Overtly health males
• Body mass index (BMI) of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive

Exclusion Criteria:

• Females
• Male participants sexually active with a pregnant partner
• Are currently enrolled in a clinical study or have participated, within the last 30 days, in a clinical study
• Have participated in a radiolabeled drug study within the previous 4 months
• Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders
• Have a history of Gilbert's syndrome
• Have history or presence of psychiatric disorders
• Show evidence of human immunodeficiency virus (HIV) infection
• Show evidence of hepatitis C
• Show evidence of hepatitis B